BioCryst Releases New Data on ORLADEYO and Navenibart
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 12 2026
0mins
Source: NASDAQ.COM
- ORLADEYO Efficacy: In the APeX-P study, patients treated with ORLADEYO experienced only 0.169 hereditary angioedema (HAE) attacks per month, a significant reduction from 0.691 attacks on standard-of-care therapies, highlighting the drug's effectiveness in lowering attack frequency.
- Standard Treatment Comparison: Over a 12-week observation period, patients on standard treatment averaged 22 HAE attacks, which dropped to just 3 attacks with ORLADEYO, indicating its potential to significantly improve patients' quality of life through long-term prevention of HAE attacks.
- Navenibart Development Progress: BioCryst is developing Navenibart as a long-acting treatment, with preliminary data showing effective reduction of moderate to severe HAE attacks across various body mass index (BMI) and age groups, supporting its application in future clinical trials.
- Clinical Trial Support: The Phase 1b/2 ALPHA-STAR trial results for Navenibart indicate reduced on-demand medication use among treated patients, with good drug tolerability, laying the groundwork for its upcoming Phase 3 ALPHA-ORBIT trial, which could offer new treatment options for HAE patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCRX
Wall Street analysts forecast BCRX stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 10.170
Low
8.00
Averages
19.45
High
32.00
Current: 10.170
Low
8.00
Averages
19.45
High
32.00
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vertex's $10B Crinetics Acquisition Sparks Biotech M&A Speculation
- M&A Activity Revived: Vertex's acquisition of Crinetics for $10 billion at $85 per share, representing a 102% premium, not only strengthens Vertex's foothold in rare endocrine diseases but also ignites speculation around VKTX and BCRX, leading to a broad rally in biotech stocks.
- VKTX's Positive Outlook: Viking Therapeutics saw a 9% stock increase post-announcement, with analysts projecting a 12-month target of $92.58, indicating a 120% upside, reflecting strong market confidence in its obesity drug VK2735, especially with upcoming Q3 maintenance data as a key catalyst.
- BCRX's Clear Benefits: BioCryst's shares rose 8%, with a 12-month target of $21.90 implying a 99% upside, bolstered by strong performance from its rare disease products Orladeyo and Navenibart, enhancing its competitive position in the market.
- Investor Sentiment Shift: Retail interest in VKTX and BCRX surged, with VKTX sentiment flipping from bearish to bullish as message volume jumped 400%, while BCRX sentiment turned extremely bullish from neutral, indicating strong investor interest and confidence in both stocks.
See More
Crinetics Hits Record High After Vertex's $10 Billion Acquisition
- Significant Acquisition Premium: Crinetics Pharmaceuticals' stock soared to $83.63 after Vertex agreed to acquire the company for approximately $10 billion, with an offer of $85 per share representing a 102% premium over Monday's closing price, marking Vertex's largest acquisition to date and boosting market confidence in Crinetics.
- Positive Market Reaction: Crinetics shares surged 98%, while Dominion Energy and BioCryst gained 0.8% and 8%, respectively, indicating investor preference for companies linked to major acquisition activity and AI infrastructure demand, driving these stocks to new 52-week highs.
- Optimistic Outlook for Dominion: Dominion Energy's stock climbed to $70.59, a three-year high, benefiting from its extensive pipeline of power projects in Northern Virginia and its proposed merger with NextEra Energy, highlighting its growing role in supplying electricity to AI data centers.
- BioCryst's Strategic Shift: BioCryst Pharmaceuticals reached a new 52-week high of $11.02 as it plans to close its Birmingham research center and partner with external firms to cut costs and achieve profitability, with RBC Capital raising its price target to $14, reflecting strong momentum in biotech stocks.
See More
Crinetics Hits Record High After Vertex Acquisition Deal
- Significant Acquisition Premium: Crinetics Pharmaceuticals' stock reached $83.63 after Vertex agreed to acquire the company for approximately $10 billion, with a purchase price of $85 per share, representing a 102% premium over Monday's closing price, marking Vertex's largest acquisition to date and enhancing its market position in the endocrine sector.
- Positive Market Reaction: Crinetics surged 98%, while Dominion Energy and BioCryst gained 0.8% and 8%, respectively, indicating strong investor preference for companies linked to major acquisition activity and AI infrastructure demand, driving these stocks to new 52-week highs.
- Dominion Benefits from AI Demand: Dominion Energy's stock climbed to a three-year high of $70.59 as its role in supplying electricity to data centers in Northern Virginia becomes increasingly significant, expected to benefit from rising AI-related electricity demand, although retail sentiment slightly turned bearish.
- BioCryst Focuses on Cash Flow: BioCryst shares hit a new high of $11.02 as the company plans to close its Birmingham research center and rely on external partners for early-stage research, expected to cut costs and accelerate profitability, with RBC Capital raising its price target to $14, reflecting strong momentum in biotech stocks.
See More
BioCryst Accelerates Rare Disease Pipeline Growth Through Strategic Shift
- Strategic Shift: BioCryst announced the discontinuation of its internal discovery programs and the closure of its Birmingham, Alabama, Discovery Center of Excellence, prioritizing external innovation to build a sustainable rare disease pipeline in a more nimble and capital-efficient manner.
- Clinical Trial Progress: Enrollment for the Phase 3 ALPHA-ORBIT study of navenibart has been completed, positioning it to potentially be the first hereditary angioedema therapy with both 3- and 6-month dosing, with efficacy data expected in Q3 2027.
- Improved Financial Outlook: BioCryst has revised its 2026 non-GAAP operating expense guidance down from $450-$470 million to $420-$440 million, demonstrating the company's ability to control costs during its transition.
- Product Launch Plans: The previously disclosed manufacturing delay of ORLADEYO oral pellets has been resolved, with the product expected to be available in early August 2026, further enhancing the company's competitive position in the rare disease market.
See More
BioCryst Pharmaceuticals Shares Surge Amid Positive Therapy Data
- Strong Stock Performance: BioCryst Pharmaceuticals (BCRX) shares have surged for six consecutive trading days, gaining over 33% and reaching a 52-week high on Thursday, reflecting strong investor confidence in its future performance.
- Market Sentiment Extremely Bullish: Data from Stocktwits indicates that retail sentiment for BCRX remains in the 'extremely bullish' zone, with message volumes surging 360% within a 24-hour period, suggesting investor anticipation for a breakout above key resistance levels.
- Promising Orladeyo Therapy: Recent data from BioCryst shows that its Orladeyo therapy significantly reduced hereditary angioedema attacks in children aged 2 to 12, with medical care needs dropping from 22 to just 3, and projected revenue for Orladeyo in 2026 is expected to reach $625 million to $645 million, accounting for 97.7% to 98.4% of total revenue.
- Advancement in Drug Development: BioCryst is also advancing a potential treatment for Netherton syndrome, with Phase 1 data expected by year-end, further enhancing the company's competitive position in the rare disease market.
See More
Bitdeer and BioCryst Options Trading Activity Surges
- Surge in Bitdeer Options: Bitdeer Technologies Group (BTDR) has seen an options trading volume of 60,785 contracts today, equating to approximately 6.1 million shares, which represents about 49.9% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- High Call Option Activity: Within BTDR, the $20 strike call option has been particularly active, with 30,291 contracts traded today, representing around 3.0 million shares, reflecting a strong bullish sentiment among investors regarding the stock's potential upside.
- BioCryst Options Trading: BioCryst Pharmaceuticals Inc (BCRX) has recorded an options trading volume of 21,183 contracts today, translating to approximately 2.1 million shares, which is about 49.1% of its average daily trading volume over the past month, showcasing market interest in its growth prospects.
- Active BCRX Call Options: For BCRX, the $15 strike call option has also seen significant activity, with 8,347 contracts traded today, representing approximately 834,700 shares, indicating investor optimism about the company's future performance.
See More
Vertex's $10B Crinetics Acquisition Sparks Biotech M&A Speculation
- M&A Activity Revived: Vertex's acquisition of Crinetics for $10 billion at $85 per share, representing a 102% premium, not only strengthens Vertex's foothold in rare endocrine diseases but also ignites speculation around VKTX and BCRX, leading to a broad rally in biotech stocks.
- VKTX's Positive Outlook: Viking Therapeutics saw a 9% stock increase post-announcement, with analysts projecting a 12-month target of $92.58, indicating a 120% upside, reflecting strong market confidence in its obesity drug VK2735, especially with upcoming Q3 maintenance data as a key catalyst.
- BCRX's Clear Benefits: BioCryst's shares rose 8%, with a 12-month target of $21.90 implying a 99% upside, bolstered by strong performance from its rare disease products Orladeyo and Navenibart, enhancing its competitive position in the market.
- Investor Sentiment Shift: Retail interest in VKTX and BCRX surged, with VKTX sentiment flipping from bearish to bullish as message volume jumped 400%, while BCRX sentiment turned extremely bullish from neutral, indicating strong investor interest and confidence in both stocks.
See More
Crinetics Hits Record High After Vertex's $10 Billion Acquisition
- Significant Acquisition Premium: Crinetics Pharmaceuticals' stock soared to $83.63 after Vertex agreed to acquire the company for approximately $10 billion, with an offer of $85 per share representing a 102% premium over Monday's closing price, marking Vertex's largest acquisition to date and boosting market confidence in Crinetics.
- Positive Market Reaction: Crinetics shares surged 98%, while Dominion Energy and BioCryst gained 0.8% and 8%, respectively, indicating investor preference for companies linked to major acquisition activity and AI infrastructure demand, driving these stocks to new 52-week highs.
- Optimistic Outlook for Dominion: Dominion Energy's stock climbed to $70.59, a three-year high, benefiting from its extensive pipeline of power projects in Northern Virginia and its proposed merger with NextEra Energy, highlighting its growing role in supplying electricity to AI data centers.
- BioCryst's Strategic Shift: BioCryst Pharmaceuticals reached a new 52-week high of $11.02 as it plans to close its Birmingham research center and partner with external firms to cut costs and achieve profitability, with RBC Capital raising its price target to $14, reflecting strong momentum in biotech stocks.
See More
Crinetics Hits Record High After Vertex Acquisition Deal
- Significant Acquisition Premium: Crinetics Pharmaceuticals' stock reached $83.63 after Vertex agreed to acquire the company for approximately $10 billion, with a purchase price of $85 per share, representing a 102% premium over Monday's closing price, marking Vertex's largest acquisition to date and enhancing its market position in the endocrine sector.
- Positive Market Reaction: Crinetics surged 98%, while Dominion Energy and BioCryst gained 0.8% and 8%, respectively, indicating strong investor preference for companies linked to major acquisition activity and AI infrastructure demand, driving these stocks to new 52-week highs.
- Dominion Benefits from AI Demand: Dominion Energy's stock climbed to a three-year high of $70.59 as its role in supplying electricity to data centers in Northern Virginia becomes increasingly significant, expected to benefit from rising AI-related electricity demand, although retail sentiment slightly turned bearish.
- BioCryst Focuses on Cash Flow: BioCryst shares hit a new high of $11.02 as the company plans to close its Birmingham research center and rely on external partners for early-stage research, expected to cut costs and accelerate profitability, with RBC Capital raising its price target to $14, reflecting strong momentum in biotech stocks.
See More
BioCryst Accelerates Rare Disease Pipeline Growth Through Strategic Shift
- Strategic Shift: BioCryst announced the discontinuation of its internal discovery programs and the closure of its Birmingham, Alabama, Discovery Center of Excellence, prioritizing external innovation to build a sustainable rare disease pipeline in a more nimble and capital-efficient manner.
- Clinical Trial Progress: Enrollment for the Phase 3 ALPHA-ORBIT study of navenibart has been completed, positioning it to potentially be the first hereditary angioedema therapy with both 3- and 6-month dosing, with efficacy data expected in Q3 2027.
- Improved Financial Outlook: BioCryst has revised its 2026 non-GAAP operating expense guidance down from $450-$470 million to $420-$440 million, demonstrating the company's ability to control costs during its transition.
- Product Launch Plans: The previously disclosed manufacturing delay of ORLADEYO oral pellets has been resolved, with the product expected to be available in early August 2026, further enhancing the company's competitive position in the rare disease market.
See More
BioCryst Pharmaceuticals Shares Surge Amid Positive Therapy Data
- Strong Stock Performance: BioCryst Pharmaceuticals (BCRX) shares have surged for six consecutive trading days, gaining over 33% and reaching a 52-week high on Thursday, reflecting strong investor confidence in its future performance.
- Market Sentiment Extremely Bullish: Data from Stocktwits indicates that retail sentiment for BCRX remains in the 'extremely bullish' zone, with message volumes surging 360% within a 24-hour period, suggesting investor anticipation for a breakout above key resistance levels.
- Promising Orladeyo Therapy: Recent data from BioCryst shows that its Orladeyo therapy significantly reduced hereditary angioedema attacks in children aged 2 to 12, with medical care needs dropping from 22 to just 3, and projected revenue for Orladeyo in 2026 is expected to reach $625 million to $645 million, accounting for 97.7% to 98.4% of total revenue.
- Advancement in Drug Development: BioCryst is also advancing a potential treatment for Netherton syndrome, with Phase 1 data expected by year-end, further enhancing the company's competitive position in the rare disease market.
See More
Bitdeer and BioCryst Options Trading Activity Surges
- Surge in Bitdeer Options: Bitdeer Technologies Group (BTDR) has seen an options trading volume of 60,785 contracts today, equating to approximately 6.1 million shares, which represents about 49.9% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- High Call Option Activity: Within BTDR, the $20 strike call option has been particularly active, with 30,291 contracts traded today, representing around 3.0 million shares, reflecting a strong bullish sentiment among investors regarding the stock's potential upside.
- BioCryst Options Trading: BioCryst Pharmaceuticals Inc (BCRX) has recorded an options trading volume of 21,183 contracts today, translating to approximately 2.1 million shares, which is about 49.1% of its average daily trading volume over the past month, showcasing market interest in its growth prospects.
- Active BCRX Call Options: For BCRX, the $15 strike call option has also seen significant activity, with 8,347 contracts traded today, representing approximately 834,700 shares, indicating investor optimism about the company's future performance.
See More
